Ge Long Hui·2025-11-25 08:03Core Viewpoint - Alibaba Health (0241.HK) experienced a significant stock price increase, rising nearly 6% and surpassing HKD 6, with a latest market capitalization of HKD 96.4 billion [1] Group 1: Demand Surge - Demand for antiviral drugs for influenza has notably increased, with the number of buyers rising fivefold over the past two weeks (November 10 to 23) [1] - The purchase of the antiviral drug Mabalosavir saw a more than sixfold increase, leading the growth in demand [1] - The number of buyers for antiviral oral liquids also increased by 50% [1] Group 2: Market Insights - Experts indicate that the H3N2 strain circulating this year is different from previous years, resulting in lower immunity among the population and facilitating easier transmission [1] - As a platform, Alibaba Health benefits from both self-operated businesses (such as Alibaba Health Pharmacy) and commissions and service fees from third-party merchants on the Tmall Medicine platform [1] - The fivefold increase in demand for antiviral drugs directly translates to a surge in order volume and sales, leading to increased revenue and profit for Alibaba Health [1]